Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,292,407 shares of the life sciences company’s stock after purchasing an additional 32,270 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.81% of Illumina worth $172,704,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of ILMN. Golden State Wealth Management LLC acquired a new position in shares of Illumina during the fourth quarter worth $32,000. Assetmark Inc. boosted its stake in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina in the fourth quarter valued at $45,000. Lee Danner & Bass Inc. acquired a new position in Illumina in the fourth quarter valued at $48,000. Finally, V Square Quantitative Management LLC boosted its stake in Illumina by 50.6% in the fourth quarter. V Square Quantitative Management LLC now owns 393 shares of the life sciences company’s stock valued at $52,000 after acquiring an additional 132 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 1.5%

Shares of ILMN opened at $80.54 on Friday. The firm has a market cap of $12.75 billion, a PE ratio of -10.49, a price-to-earnings-growth ratio of 1.60 and a beta of 1.35. The company’s fifty day moving average is $78.23 and its two-hundred day moving average is $109.53. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Illumina’s revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the business earned $0.98 EPS. Analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the subject of several research analyst reports. Citigroup decreased their price objective on shares of Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research note on Monday, April 7th. Robert W. Baird decreased their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Morgan Stanley decreased their price objective on shares of Illumina from $136.00 to $100.00 and set an “equal weight” rating for the company in a research note on Monday, May 12th. Finally, Canaccord Genuity Group decreased their target price on shares of Illumina from $92.00 to $87.00 and set a “hold” rating for the company in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $128.15.

Insider Activity at Illumina

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of Illumina stock in a transaction that occurred on Monday, May 12th. The shares were acquired at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the acquisition, the chief financial officer now owns 24,906 shares of the company’s stock, valued at $2,022,616.26. The trade was a 32.44% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.60% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.